← Volver a la portada
Estados Unidos · Plataformas y datos · The Motley Fool

Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?

Publicado por The Motley Fool · Estados Unidos hace 11 h
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027?
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027? · The Motley Fool

Resumen detallado

Grail's cancer blood test faces a setback in a major UK trial, while Tempus AI's data business is growing fast but still losing money. The two carry very different risk profiles.

Investors seeking exposure to the cutting edge of diagnostics often face a choice between specialized early detection and broad data platforms. Does Grail Inc. (GRAL +5.93%) or Tempus AI (TEM -3.40%) represent the better long-term opportunity?

Grail focuses on pioneering multi-cancer early detection, catching the disease when it is most treatable. Tempus AI builds a massive data ecosystem, using artificial intelligence to help physicians and drugmakers personalize patient care. Both companies occupy unique niches, utilizing genomics to transform modern medicine and improve patient outcomes globally.

Grail specializes in developing blood tests for early cancer detection among healthcare stocks, primarily through its flagship Galleri product. The company works closely with the National Health Service (NHS) in the U.K. on a large-scale clinical trial, though recent findings are currently under review. Its primary customers include self-insured employers and life insurance providers, with additional partnerships in precision oncology.

In its latest annual report, filed for the fiscal year ended Dec. 31, 2025, Grail reported that revenue reached about $147.2 million. This represents growth of roughly 17.2% compared to the prior fiscal year. The company recorded a net loss of about $408.4 million for this period, resulting in a negative net margin of approximately 278%.

As of its December 2025 balance sheet, the company carries a debt-to-equity ratio of 0.0x, indicating it has no debt. The current ratio, which measures a firm's ability to cover short-term obligations with current assets, sits at a strong 12.0x. Free cash flow for FY 2025 was negative $299.9 million, reflecting the company's continued heavy investment in its clinical research and commercial infrastructure.

Tempus AI operates a sophisticated platform that combines multimodal data with artificial intelligence to support precision medicine.

For FY 2025, revenue hit about $1.28 billion, a sharp increase of…

On its…

Inicio del artículo, extracto de The Motley Fool. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar